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Abstract 
  
Multiple sclerosis (MS) is a chronic inflammatory demyelinating and degenerative disease of 
the central nervous system. It is the most common non-traumatic cause of chronic disability 
in young adults. An early and accurate diagnosis, and effective disease modifying treatment 
(DMT) are key elements of optimum care for people with MS (pwMS). 
  
Magnetic resonance imaging (MRI) has become a critical tool to confirm the presence of 
dissemination in space and time of lesions characteristic of inflammatory demyelination, a 
cornerstone of MS diagnosis, over and above exclusion of numerous differential diagnoses. 
In the modern era of early and highly effective DMT, follow-up of pwMS also relies heavily 
on MRI, to both confirm efficacy and for pharmacovigilance. 
  
Since criteria for MS rely heavily on MRI, an agreed standardized acquisition and reporting 
protocol enabling efficient and equitable application across the UK is desirable. Following a 
recent meeting of MS experts in London (UK), we make recommendations for a 
standardized UK MRI protocol that captures the diagnostic phase as well as monitoring for 
safety and treatment efficacy once the diagnosis is established. Our views take into account 
issues arising from the (repeated) use of contrast agents as well as the advent of (semi-) 
automated tools to further optimise disease monitoring in pwMS. 
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Multiple sclerosis (MS) is an inflammatory demyelinating and degenerative disease of the central 
nervous system, and the most common non-traumatic cause of chronic disability in young adults (1). 
MS affects over 120,000 people in the UK (2). Early and accurate diagnosis, and effective disease 
modifying treatment (DMT) are key elements of optimum care for people with MS (pwMS) (3,4). 
 
Ever since an International Panel chaired by the late Ian McDonald recommended its eponymous 
criteria for the diagnosis of MS, magnetic resonance imaging (MRI) has become a critical tool to 
confirm the presence of dissemination in space and time of lesions characteristic of inflammatory 
demyelination, cornerstones of MS, and to exclude numerous differential diagnoses (5). In the 
modern era of early and highly effective DMT, follow-up of pwMS also relies heavily on MRI, for 
disease control and pharmacovigilance. 
 
Since MRI criteria for MS are based on specific techniques, agreed standardized acquisition and 
reporting protocols across the UK are desirable. This will facilitate continued monitoring of pwMS 
moving to different parts of the country. In the longer term, it also will provide comparable imaging 
and outcomes data that, when considered together, could inform better clinical decision-making. To 
discover whether any de facto standardisation already is in place – despite the lack of formal 
agreement – we undertook a brief survey among neuroradiology trainees. A link to the survey, open 
between 2nd of January and 30th of March 2018, was sent out twice using the email database of the 
British Society for Neuroradiologists trainee list. Ten trainees from eight centres (Bristol, Cambridge, 
Leeds, Manchester, Newcastle, Norwich and two in London) responded. Heterogeneity of scanning 
protocols for MS among institutions was evident: only 50% acquired any volumetric sequences, and 
there was no consensus on the non-volumetric FLAIR, with coronal, sagittal and axial planes used in 
different centres. Of note, only a single centre used gadolinium contrast by default in all (diagnostic 
and follow-up) investigations of pwMS. The remainder of the centres restricted routine use of 
contrast administration to diagnostic scans. MRI measures of disease burden and its progression 
thus are not comparable across UK centres. Albeit based on a limited sample, this illustrates the 
need for standardisation. 
 
Whilst the diagnostic principles for MS have recently undergone their third revision (6), there has 
perhaps been lesser emphasis on acquisition techniques. However, to provide an equitable service 
across the country within the financial constraints of the NHS (7), an efficient way to enable best 
practice in MS that covers the diagnostic and follow-up/monitoring phases is warranted. There is no 
need to “reinvent the wheel”, since both the Magnetic Resonance Imaging in MS (MAGNIMS) (8) and 
the Consortium of MS Centres (CMSC) (9) networks have recently updated their evidence-based 
guidance on MRI in MS. Detailed suggestions provided by a Swedish consensus statement provide 
further reference points for a UK protocol covering the techniques used, timelines for scanning, as 
well as requesting and reporting guidelines (10) (Table 1). However, while there are communalities 
among these protocols, most of them are too long (and partially redundant) to be used efficiently in 
the NHS.  There is a need to develop a more concise, cost effective protocol for the UK which will 
balance the cost of scanning time and the information provided. 
 
A cornerstone of most recommended brain protocols is 3D rather than 2D FLAIR to (i) improve 
sensitivity for lesion detection and (ii) enable reconstruction in any desired plane thereby mitigating 
differences in the longitudinal assessment due to imperfect scanning plane alignment and patient 
repositioning. On modern scanners, such 3D-FLAIR sequences can now be obtained in under 5 
minutes. The general advantage of using 3D sequences is that longitudinal scans can be registered 
and subtracted, which greatly facilitates detection of new lesions and improves inter-observer 
variability (11) 
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Detection of disease activity through new FLAIR lesions may also reduce the need to use gadolinium, 
which carries the risk of deposition in the CNS.  
Recently, several (semi-)automated tools to estimate MS lesion changes as well as whole brain and 
white/grey matter volumes have been CE marked and some have been FDA approved (12). These 
new technologies are designed to not only assist the radiologist in the detection of lesions, but also 
to quantify volume changes. Evidence suggests that using these tools to guide radiologists may 
reduce both inter-observer variability and reading time (13). Moreover, brain volume changes can be 
reliably quantified in ways that may contribute to clinical decisions. While the data is not yet 
available to evaluate the utility of these measures in clinical practice and current expert guidelines 
thus do not recommend their routine use (8), it would be prudent to consider these and other 
emerging analytical technologies for clinical decision support when formulating a UK protocol. 
With highly active DMT focussing on the adaptive immune response, characteristic risk profiles have 
emerged that warrant use of specific methods for MRI monitoring.  The major example of this is 
monitoring for the risk of progressive multifocal leukoencephalopathy (PML) due to the long term 
treatment of pwMS with natalizumab (Tysabri) and - rarely - other DMTs for pwMS (14). Other DMT-
associated opportunistic infections also are being recognized (15). As highly active DMT use become 
commonplace across the country, mitigation of the risks by frequent (3-6 monthly) MRI monitoring is 
needed, for which an  abbreviated protocol including only 3D-FLAIR, 2D-T2 and DWI is recommended 
(https://ms-pml.org/). 
 
Since markers of MS disease activity based on biofluids are only slowly emerging, the quality of both 
diagnostic as well as follow-up MRI will, for the time being, remain key for the optimum care of 
pwMS. This has most recently been recognized by a dedicated satellite panel at the annual meeting 
of the Association of British Neurologists in April 2018. We encourage the neuroradiology 
community in the UK to take the next step and develop a nationwide efficient protocol that enables 
best care as well as equity in the diagnosis and follow-up of pwMS across the NHS. 
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Table 1: Recommended MRI protocols for diagnosis and follow-up of people with multiple 
sclerosis adapted from references 8–10 (acquisition times). 
 
Consortium of Multiple Sclerosis Centres Task Force  
Core sequences  Optional sequences  
Anatomic 3D inversion recovery (IR) T1 gradient echo 
attenuation (5:21) 
 Axial proton attenuation  
Gadolinium single dose (0.1 mmol/kg for 30 seconds) 
2D (3:20) 
 Pre- or post-gadolinium axial T1 spin-
echo (for chronic black holes) (3:20) 
 
3D sagittal T2 weighted image (WI) FLAIR within T2 lesions   SWI for identification of CVS (3:02)  
3D T2WI b    
2D axial diffusion weighted imaging (DWI) (5-mm 
sections, no gap) (1:52) 
   
3D FLASH (non-IR prepared) post-gadolinium    
3D series (eg 1.0-1.5mm thickness); typically 
reconstructed to 3mm for display and comparison of 
lesion counts 
   
    
Swedish Multiple Sclerosis Association and the Swedish Neuroradiological Society 
Diagnostic  Follow-up  
3D T1 (Pre-contrast) (5:21)  Gadolinium-based contrast agents  
Haemorrhage sensitive sequence (SWI, gradient recalled 
echo or fast field echo) (3:02) 
 Axial T2 (2:20)  
DWI (1:52)  3D T2 FLAIR (5:42)  
Gadolinium-based contrast agents  3D post-gadolinium T1 (5:21)  
Axial T2 (2:20)    
3D T2-FLAIR (5:42)    
3D T1 (post-gadolinium) (5:21)    
    
MAGNIMS Standardized MRI Protocol    
Brain – diagnostic  Follow-up  
Axial 2D PD or T2-FLAIR (2:44)  Axial 2D PD (2:20) or T2-FLAIR (2:44)  
Axial 2D T2-weighted (2:20)  Axial 2D T2-weighted (2:20)  
Sagittal T2-FLAIR 2D (2:44) or 3D (5:42)   
Contrast-enhanced T1-weighted 2D 
(3:20) or 3D (5:21) 
 
Contrast-enhanced T1-weighted 2D (3:20) or 3D (5:21)     
    
Spinal cord – diagnostic    
Sagittal 2D PD*/T2-weighted sequences (3:36)    
Sagittal 2D contrast-enhanced T1-weighted (2:00)    
*STIR can be used alternatively    
Optional: axial 2D T2-weighed sequences    
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Multiple sclerosis (MS) is an inflammatory demyelinating and degenerative disease of the central 
nervous system, and the most common non-traumatic cause of chronic disability in young adults (1). 
MS affects over 120,000 people in the UK (2). Early and accurate diagnosis, and effective disease 
modifying treatment (DMT) are key elements of optimum care for people with MS (pwMS) (3,4). 
 
Ever since an International Panel chaired by the late Ian McDonald recommended its eponymous 
criteria for the diagnosis of MS, magnetic resonance imaging (MRI) has become a critical tool to 
confirm the presence of dissemination in space and time of lesions characteristic of inflammatory 
demyelination, cornerstones of MS, and to exclude numerous differential diagnoses (5). In the 
modern era of early and highly effective DMT, follow-up of pwMS also relies heavily on MRI, for 
disease control and pharmacovigilance. 
 
Since MRI criteria for MS are based on specific techniques, agreed standardized acquisition and 
reporting protocols across the UK are desirable. This will facilitate continued monitoring of pwMS 
moving to different parts of the country. In the longer term, it also will provide comparable imaging 
and outcomes data that, when considered together, could inform better clinical decision-making. To 
discover whether any de facto standardisation already is in place – despite the lack of formal 
agreement – we undertook a brief survey among neuroradiology trainees. A link to the survey, open 
between 2nd of January and 30th of March 2018, was sent out twice using the email database of the 
British Society for Neuroradiologists trainee list. Ten trainees from eight centres (Bristol, Cambridge, 
Leeds, Manchester, Newcastle, Norwich and two in London) responded. Heterogeneity of scanning 
protocols for MS among institutions was evident: only 50% acquired any volumetric sequences, and 
there was no consensus on the non-volumetric FLAIR, with coronal, sagittal and axial planes used in 
different centres. Of note, only a single centre used gadolinium contrast by default in all (diagnostic 
and follow-up) investigations of pwMS. The remainder of the centres restricted routine use of 
contrast administration to diagnostic scans. MRI measures of disease burden and its progression 
thus are not comparable across UK centres. Albeit based on a limited sample, this illustrates the 
need for standardisation. 
 
Whilst the diagnostic principles for MS have recently undergone their third revision (6), there has 
perhaps been lesser emphasis on acquisition techniques. However, to provide an equitable service 
across the country within the financial constraints of the NHS (7), an efficient way to enable best 
practice in MS that covers the diagnostic and follow-up/monitoring phases is warranted. There is no 
need to “reinvent the wheel”, since both the Magnetic Resonance Imaging in MS (MAGNIMS) (8) and 
the Consortium of MS Centres (CMSC) (9) networks have recently updated their evidence-based 
guidance on MRI in MS. Detailed suggestions provided by a Swedish consensus statement provide 
further reference points for a UK protocol covering the techniques used, timelines for scanning, as 
well as requesting and reporting guidelines (10) (Table 1). However, while there are communalities 
among these protocols, most of them are too long (and partially redundant) to be used efficiently in 
the NHS.  There is a need to develop a more concise, cost effective protocol for the UK which will 
balance the cost of scanning time and the information provided. 
 
A cornerstone of most recommended brain protocols is 3D rather than 2D FLAIR to (i) improve 
sensitivity for lesion detection and (ii) enable reconstruction in any desired plane thereby mitigating 
differences in the longitudinal assessment due to imperfect scanning plane alignment and patient 
repositioning. On modern scanners, such 3D-FLAIR sequences can now be obtained in under 5 
minutes. The general advantage of using 3D sequences is that longitudinal scans can be registered 
and subtracted, which greatly facilitates detection of new lesions and improves inter-observer 
variability (11) 
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Detection of disease activity through new FLAIR lesions may also reduce the need to use gadolinium, 
which carries the risk of deposition in the CNS.  
Recently, several (semi-)automated tools to estimate MS lesion changes as well as whole brain and 
white/grey matter volumes have been CE marked and some have been FDA approved (12). These 
new technologies are designed to not only assist the radiologist in the detection of lesions, but also 
to quantify volume changes. Evidence suggests that using these tools to guide radiologists may 
reduce both inter-observer variability and reading time (13). Moreover, brain volume changes can be 
reliably quantified in ways that may contribute to clinical decisions. While the data is not yet 
available to evaluate the utility of these measures in clinical practice and current expert guidelines 
thus do not recommend their routine use (8), it would be prudent to consider these and other 
emerging analytical technologies for clinical decision support when formulating a UK protocol. 
With highly active DMT focussing on the adaptive immune response, characteristic risk profiles have 
emerged that warrant use of specific methods for MRI monitoring.  The major example of this is 
monitoring for the risk of progressive multifocal leukoencephalopathy (PML) due to the long term 
treatment of pwMS with natalizumab (Tysabri) and - rarely - other DMTs for pwMS (14). Other DMT-
associated opportunistic infections also are being recognized (15). As highly active DMT use become 
commonplace across the country, mitigation of the risks by frequent (3-6 monthly) MRI monitoring is 
needed, for which an  abbreviated protocol including only 3D-FLAIR, 2D-T2 and DWI is recommended 
(https://ms-pml.org/). 
 
Since markers of MS disease activity based on biofluids are only slowly emerging, the quality of both 
diagnostic as well as follow-up MRI will, for the time being, remain key for the optimum care of 
pwMS. This has most recently been recognized by a dedicated satellite panel at the annual meeting 
of the Association of British Neurologists in April 2018. We encourage the neuroradiology 
community in the UK to take the next step and develop a nationwide efficient protocol that enables 
best care as well as equity in the diagnosis and follow-up of pwMS across the NHS. 
 
 
  
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 
 
 
BJR-D-18-00926 – Schmierer, et al. Towards a standard MRI protocol for multiple sclerosis across the UK 
Table 1: Recommended MRI protocols for diagnosis and follow-up of people with multiple 
sclerosis adapted from references (8–10) (acquisition times). 
 
Consortium of Multiple Sclerosis Centres Task Force  
Core sequences  Optional sequences  
Anatomic 3D inversion recovery (IR) T1 gradient echo 
attenuation (5:21) 
 Axial proton attenuation  
Gadolinium single dose (0.1 mmol/kg for 30 seconds) 
2D (3:20) 
 Pre- or post-gadolinium axial T1 spin-
echo (for chronic black holes) (3:20) 
 
3D sagittal T2 weighted image (WI) FLAIR within T2 lesions   SWI for identification of CVS (3:02)  
3D T2WI b    
2D axial diffusion weighted imaging (DWI) (5-mm 
sections, no gap) (1:52) 
   
3D FLASH (non-IR prepared) post-gadolinium    
3D series (eg 1.0-1.5mm thickness); typically 
reconstructed to 3mm for display and comparison of 
lesion counts 
   
    
Swedish Multiple Sclerosis Association and the Swedish Neuroradiological Society 
Diagnostic  Follow-up  
3D T1 (Pre-contrast) (5:21)  Gadolinium-based contrast agents  
Haemorrhage sensitive sequence (SWI, gradient recalled 
echo or fast field echo) (3:02) 
 Axial T2 (2:20)  
DWI (1:52)  3D T2 FLAIR (5:42)  
Gadolinium-based contrast agents  3D post-gadolinium T1 (5:21)  
Axial T2 (2:20)    
3D T2-FLAIR (5:42)    
3D T1 (post-gadolinium) (5:21)    
    
MAGNIMS Standardized MRI Protocol    
Brain – diagnostic  Follow-up  
Aaxial 2D PD or T2-FLAIR (2:44)  Axial 2D PD (2:20) or T2-FLAIR (2:44)  
Aaxial 2D T2-weighted (2:20)  Aaxial 2D T2-weighted (2:20)  
Ssagittal T2-FLAIR 2D (2:44) or 3D (5:42)   
Ccontrast-enhanced T1-weighted 2D 
(3:20) or 3D (5:21) 
 
Contrast-enhanced T1-weighted 2D (3:20) or 3D (5:21)     
    
Spinal cord – diagnostic    
Ssagittal 2D PD*/T2-weighted sequences (3:36)    
Sagittal 2D contrast-enhanced T1-weighted (2:00)    
*STIR can be used alternatively    
Ooptional: axial 2D T2-weighed sequences    
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